FLT3 and acute myeloid leukemia: Further, in acute myeloid leukaemia (AML), HoxB2 and HoxB3 were identified as negative regulators of the FLT3 receptor tyrosine kinase, with their mutations associated with carcinogenic events in around 30% of AML cases [34].